Difference between revisions of "Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations"
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
(finished adding citation) |
(reordered citations to be numerically ordered) |
||
| Line 56: | Line 56: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6">{{Cite journal|last=Bk|first=Zehentner|last2=L|first2=Hartmann|last3=Kr|first3=Johnson|last4=Cf|first4=Stephenson|last5=Db|first5=Chapman|last6=Me|first6=de Baca|last7=Da|first7=Wells|last8=Mr|first8=Loken|last9=B|first9=Tirtorahardjo|date=2012|title=Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations|url=https://pubmed.ncbi.nlm.nih.gov/23010713/|language=en|pmid=23010713}}</ref>, 22833442 (2012)<ref name=":7">{{Cite journal|last=M|first=Stevens-Kroef|last2=Do|first2=Weghuis|last3=S|first3=Croockewit|last4=L|first4=Derksen|last5=J|first5=Hooijer|last6=N|first6=Elidrissi-Zaynoun|last7=A|first7=Siepman|last8=A|first8=Simons|last9=Ag|first9=Kessel|date=2012|title=High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/22833442/|language=en|pmid=22833442}}</ref>, 27588520 (2016)<ref name=":8">{{Cite journal|last=N|first=Bolli|last2=Y|first2=Li|last3=V|first3=Sathiaseelan|last4=K|first4=Raine|last5=D|first5=Jones|last6=P|first6=Ganly|last7=F|first7=Cocito|last8=G|first8=Bignell|last9=Ma|first9=Chapman|date=2016|title=A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/27588520/|language=en|doi=10.1038/bcj.2016.72|pmc=PMC5056967|pmid=27588520}}</ref> |
|- | |- | ||
|1q21.2-q23 | |1q21.2-q23 | ||
| Line 63: | Line 63: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, 27588520 (2016)<ref name=":8" /> |
|- | |- | ||
|1q | |1q | ||
| Line 70: | Line 70: | ||
|Poor prognostic marker | |Poor prognostic marker | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
| rowspan="2" |2 | | rowspan="2" |2 | ||
| Line 93: | Line 93: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|3q21-23 | |3q21-23 | ||
| Line 130: | Line 130: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, 27588520 (2016)<ref name=":8" /> |
|- | |- | ||
|5p | |5p | ||
| Line 158: | Line 158: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | | | + | |24987674 (2014)<ref name=":1" /> 25145975 (2015)<ref name=":2" /> |
|- | |- | ||
|5q13.2 | |5q13.2 | ||
| Line 173: | Line 173: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | |25636340 (2015)<ref name=":0" />, | + | |25636340 (2015)<ref name=":0" />, 24987674 (2014)<ref name=":1" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|6pter-p22.3 | |6pter-p22.3 | ||
| Line 187: | Line 187: | ||
|Poor prognostic marker | |Poor prognostic marker | ||
|2 | |2 | ||
| − | |25636340 (2015)<ref name=":0" />, | + | |25636340 (2015)<ref name=":0" />, 24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|6q11.1-q13 | |6q11.1-q13 | ||
| Line 223: | Line 223: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|7p | |7p | ||
| Line 244: | Line 244: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" /> |
|- | |- | ||
| rowspan="6" |8 | | rowspan="6" |8 | ||
| Line 252: | Line 252: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | |25636340 (2015)<ref name=":0" />, | + | |25636340 (2015)<ref name=":0" />, 24987674 (2014)<ref name=":1" /> 25145975 (2015)<ref name=":2" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|8p23.1 | |8p23.1 | ||
| Line 280: | Line 280: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | |24757046 (2014)<ref name=":5" />, 27588520 (2016)<ref name=":8" />, 26338801 (2016)<ref>{{Cite journal|last=K|first=Rack|last2=S|first2=Vidrequin|last3=Jl|first3=Dargent|date=2016|title=Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases|url=https://pubmed.ncbi.nlm.nih.gov/26338801/|language=en|pmid=26338801}}</ref>, | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 27588520 (2016)<ref name=":8" />, 26338801 (2016)<ref>{{Cite journal|last=K|first=Rack|last2=S|first2=Vidrequin|last3=Jl|first3=Dargent|date=2016|title=Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases|url=https://pubmed.ncbi.nlm.nih.gov/26338801/|language=en|pmid=26338801}}</ref>, 27811368-(2016)<ref name=":9">{{Cite journal|last=P|first=Krzeminski|last2=La|first2=Corchete|last3=Jl|first3=García|last4=L|first4=López-Corral|last5=E|first5=Fermiñán|last6=Em|first6=García|last7=Aa|first7=Martín|last8=Jm|first8=Hernández-Rivas|last9=R|first9=García-Sanz|date=2016|title=Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse|url=https://pubmed.ncbi.nlm.nih.gov/27811368/|language=en|doi=10.18632/oncotarget.13025|pmc=PMC5348347|pmid=27811368}}</ref> |
|- | |- | ||
|8q24.3 | |8q24.3 | ||
| Line 295: | Line 295: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|9p | |9p | ||
| Line 302: | Line 302: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" /> |
|- | |- | ||
|9q | |9q | ||
| Line 309: | Line 309: | ||
|Recurrent | |Recurrent | ||
| | | | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" /> |
|- | |- | ||
|9q34.3 | |9q34.3 | ||
| Line 346: | Line 346: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|11p | |11p | ||
| Line 389: | Line 389: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | |25636340 (2015)<ref name=":0" />, | + | |25636340 (2015)<ref name=":0" />, 24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|12p | |12p | ||
| Line 411: | Line 411: | ||
|Poor prognostic marker | |Poor prognostic marker | ||
|1 | |1 | ||
| − | |25145975 (2015)<ref name=":2" /> 24987674 (2014)<ref name=":1" />, 22833442 (2012)<ref name=":7" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" />, 27588520 (2016)<ref name=":8" />, | + | |25145975 (2015)<ref name=":2" /> 24987674 (2014)<ref name=":1" />, 22833442 (2012)<ref name=":7" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" />, 27588520 (2016)<ref name=":8" />, |
|- | |- | ||
|13q14.11/q14.2 | |13q14.11/q14.2 | ||
| Line 433: | Line 433: | ||
|Better prognostic marker | |Better prognostic marker | ||
|2 | |2 | ||
| − | |25636340 (2015)<ref name=":0" />, | + | |25636340 (2015)<ref name=":0" />, 24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|14q/14 | |14q/14 | ||
| Line 469: | Line 469: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, |
|- | |- | ||
|15q24.1 | |15q24.1 | ||
| Line 491: | Line 491: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | |25636340 (2015)<ref name=":0" />, | + | |25636340 (2015)<ref name=":0" />, 24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|16q12.1-q12.2 | |16q12.1-q12.2 | ||
| Line 520: | Line 520: | ||
|Recurrent | |Recurrent | ||
|3, 3 | |3, 3 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" /> |
|- | |- | ||
|17p | |17p | ||
| Line 527: | Line 527: | ||
|Predictive & prognostic | |Predictive & prognostic | ||
|1 | |1 | ||
| − | | | + | |24429703-(2014)<ref name=":4" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|17p13 | |17p13 | ||
| Line 563: | Line 563: | ||
|Recurrent | |Recurrent | ||
|2, 3 | |2, 3 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
| rowspan="3" |19 | | rowspan="3" |19 | ||
| Line 571: | Line 571: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|19p/ 19p13 | |19p/ 19p13 | ||
| Line 593: | Line 593: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|20/20q | |20/20q | ||
| Line 600: | Line 600: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|20/20q | |20/20q | ||
| Line 615: | Line 615: | ||
|Recurrent | |Recurrent | ||
|1 | |1 | ||
| − | | | + | |24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
| rowspan="2" |22 | | rowspan="2" |22 | ||
| Line 623: | Line 623: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | |25636340 (2015)<ref name=":0" />, | + | |25636340 (2015)<ref name=":0" />, 24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|22q21 | |22q21 | ||
| Line 638: | Line 638: | ||
|Recurrent | |Recurrent | ||
|2 | |2 | ||
| − | | | + | |25145975 (2015)<ref name=":2" />, 22833442 (2012)<ref name=":7" /> |
|- | |- | ||
|X | |X | ||
Revision as of 14:24, 13 July 2020
| Chromosome | Region (whole chromosome or segmental, including cytobands) | Abnormality Type (gain, loss, LOH) | Relevant genes (if known) | Significance (Recurrent, Diagnostic, Prognostic, Targeted treatment) | Strength of Evidence (Level 1, 2, 3, see legend below table for criteria) | References PMID (year) |
| 1 | 1p32 | Loss | FAF1, CDKN2C | Poor prognostic marker | 1, 2 | [1] 24987674 (2014)[2], 25145975 (2015)[3] |
| 1p22.2-p22.1 | Loss | BARHL2, TGFBR3, and others; HSP90B3P, TGFER3, BRDT, EPHAX4, BTBD8 | Prognostic | 1, 3 | 24987674 (2014)[2] 25145975 (2015)[3] 26912802 (2016)[4] | |
| 1p21.3 | Loss | SNX7 | Recurrent | 2 | 24429703-(2014)[5] | |
| 1p13.2 | Loss | MAG13(kinase), BCL2 like and others | Recurrent | 3 | 24757046 (2014)[6] | |
| 1p12 | Loss | MAN1A2, FAM46C, GDAP2 | Recurrent | 2 | [1] 24987674 (2014)[2] | |
| 1p | cnLOH | Recurrent | 2 | 25145975 (2015)[3] | ||
| 1p | Loss | Recurrent | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8], 27588520 (2016)[9] | ||
| 1q21.2-q23 | Gain | CKS1B and ANP32E | Recurrent | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8], 27588520 (2016)[9] | |
| 1q | Gain | Poor prognostic marker | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | ||
| 2 | 2 | Gain | Recurrent | 2 | 22833442 (2012)[8] | |
| 2q | Loss | Recurrent | 3 | 23010713 (2012)[7] | ||
| 3 | 3 | Gain | Recurrent | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 3q21-23 | Gain | Recurrent | 2 | 25145975 (2015)[3] | ||
| 4 | 4p16.3 | Loss | FGFR3 and WHSC1 | Recurrent | 3 | 24987674 (2014)[2] |
| 4p15.2 | Loss | LGI2, SEPSECS, PI4K2B and others | Recurrent | 3 | 24987674 (2014)[2] | |
| 4q35.1 | Loss | DCTD, ING2, and others | Recurrent | 2 | 26912802 (2016)[4] | |
| 5 | 5 | Gain | Recurrent | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8], 27588520 (2016)[9] | |
| 5p | Gain | Recurrent | 3 | 24987674 (2014)[2] | ||
| 5p | Loss | Recurrent | 2 | 22833442 (2012)[8] | ||
| 5p14.3 | Gain | CDH12,10 | Recurrent | 3 | 24757046 (2014)[6] | |
| 5q | Gain | Recurrent | 2 | 24987674 (2014)[2] 25145975 (2015)[3] | ||
| 5q13.2 | Loss | OCLN, NAIP, and others | Recurrent | 2 | 26912802 (2016)[4] | |
| 6 | 6p | Gain | Recurrent | 2 | 25636340 (2015)[1], 24987674 (2014)[2], 22833442 (2012)[8] | |
| 6pter-p22.3 | Gain | Recurrent | 3 | 24987674 (2014)[2] | ||
| 6q | Loss | Poor prognostic marker | 2 | 25636340 (2015)[1], 24987674 (2014)[2], 25145975 (2015)[3], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | ||
| 6q11.1-q13 | Gain | MTRNR2L9 | Recurrent | 3 | 26912802 (2016)[4] | |
| 6q16.3 | Loss | COQR, GRIK2 | Recurrent | 3 | 24987674 (2014)[2] | |
| 6q25.3 | Loss | IGFR3 | Recurrent | 3 | 24757046 (2014)[6] | |
| 6q16.3 | Loss | COQR, GRIK2 | Recurrent | 3 | 24987674 (2014)[2] | |
| 7 | 7 | Gain | Recurrent | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 7p | Gain | Recurrent | 3 | 24987674 (2014)[2] | ||
| 7p15.2 | Gain | CBX3, etc | Recurrent | 3 | 26912802 (2016)[4] | |
| 7q | Gain | Recurrent | 2 | 24987674 (2014)[2], 25145975 (2015)[3] | ||
| 8 | 8p | Loss | Recurrent | 2 | 25636340 (2015)[1], 24987674 (2014)[2] 25145975 (2015)[3], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 8p23.1 | Loss | DEFB4 and others | Recurrent | 2 | 26912802 (2016)[4] | |
| 8p21.3/p21.2 | Loss | TNFRSF10B, DOCK5 and others | Recurrent | 3 | 24757046 (2014)[6] | |
| 8q | Gain | Recurrent | 3 | 24987674 (2014)[2] | ||
| 8q24.2 | Gain/amplification and Loss | MYC | Recurrent | 2 | 24987674 (2014)[2], 24757046 (2014)[6], 27588520 (2016)[9], 26338801 (2016)[10], 27811368-(2016)[11] | |
| 8q24.3 | Gain | MAPK15, TOP1MT, CYP11B11 (P450), ZNF41, 616, 707 and ZNF517 | Recurrent | 3 | 24757046 (2014)[6], 27811368-(2016)[11] | |
| 9 | 9 | Gain | Recurrent | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 9p | Gain | Recurrent | 2 | 24987674 (2014)[2], 25145975 (2015)[3] | ||
| 9q | Gain | Recurrent | 24987674 (2014)[2], 25145975 (2015)[3] | |||
| 9q34.3 | Gain | ZNF79, CDK9, SET | Recurrent | 3 | 24757046 (2014)[6] | |
| 10 | 10p | Loss | Recurrent | 3 | 24987674 (2014)[2] | |
| 10q | Loss | Recurrent | 3 | 24987674 (2014)[2] | ||
| 10q23.31 | Loss | PTEN | Recurrent | 2 | 16112193 (2006)[12] | |
| 11 | 11 | Gain | Recurrent | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 11p | Gain | Recurrent | 3 | 24987674 (2014)[2] | ||
| 11q | Gain | Recurrent | 2 | 25145975 (2015)[3], 23010713 (2012)[7] | ||
| 11q13.1/q13.4 | Gain | SCYL1, MAP3K11, CCND1, FGF4, FGF3, NUMA, and RELT | Recurrent | 3 | 24757046 (2014)[6] | |
| 11q22 | Loss | Recurrent | 3 | 24987674 (2014)[2] | ||
| 11q22.1-q22.3 | Homozygous Loss | BIRC3, BIRC2, MMP cluster | Recurrent | 3 | 24987674 (2014)[2], 22529291 (2012)[13] | |
| 12 | 12p | Loss | Recurrent | 2 | 25636340 (2015)[1], 24987674 (2014)[2], 24757046 (2014)[6], 22833442 (2012)[8] | |
| 12p | LOH | Recurrent | 2 | 25145975 (2015)[3], 22833442 (2012)[8] | ||
| 12p13.1 | Loss | CDKN1B, APOLD1 | Recurrent | 3 | 24987674 (2014)[2] | |
| 13 | 13q/13 | Loss | Poor prognostic marker | 1 | 25145975 (2015)[3] 24987674 (2014)[2], 22833442 (2012)[8], 23010713 (2012)[7], 24757046 (2014)[6], 27588520 (2016)[9], | |
| 13q14.11/q14.2 | Loss | TNFSF11, RB1, P2RY5, RCBTB2 | Poor prognostic marker | 1 | 24757046 (2014)[6], 24987674 (2014)[2], 25636340 (2015)[1] | |
| 13q32.2 | Loss | TGDS | Recurrent | 2 | 24429703-(2014)[5] | |
| 14 | 14q/14 | Loss | Better prognostic marker | 2 | 25636340 (2015)[1], 24987674 (2014)[2], 25145975 (2015)[3], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 14q/14 | Gain | Recurrent | 3 | 23010713 (2012)[7] | ||
| 14q | cnLOH | Recurrent | 2 | 25145975 (2015)[3], 22833442 (2012)[8] | ||
| 14q24.1-q24.3 | Loss | MLH3 | Recurrent | 2 | 26912802 (2016)[4] | |
| 14q32.32 | Homozygous Loss | RCOR1, TRAF3, AMN, CDC42BPB | Recurrent | 3 | 24987674 (2014)[2] | |
| 15 | 15 | Gain | Recurrent | 1 | 24987674 (2014)[2], 25145975 (2015)[3], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8], | |
| 15q24.1 | Gain | CYP11A1, ARID3B, CSK, etc. | Recurrent | 3 | 26912802 (2016)[4] | |
| 16 | 16p11.2 | Loss | TP53TG3 | Recurrent | 3 | 26912802 (2016)[4] |
| 16q | Loss | Recurrent | 1 | 25636340 (2015)[1], 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | ||
| 16q12.1-q12.2 | Homozygous Loss | CYLD, SALL1 | Recurrent | 3 | 24987674 (2014)[2] | |
| 16q24.3 | Loss | CBFA2T3 and others | Recurrent | 3 | 24757046 (2014)[6] | |
| 16 | cnLOH | Recurrent | 2 | 22833442 (2012)[8] | ||
| 17 | 17p/17 | Gain | Recurrent | 3, 3 | 24987674 (2014)[2], 23010713 (2012)[7] | |
| 17p | Loss | Predictive & prognostic | 1 | 24429703-(2014)[5], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | ||
| 17p13 | Loss | ATP1B2, TP53, WRAP5, EFNB3 | Predictive & prognostic | 1 | 24987674 (2014)[2], 27588520 (2016)[9] | |
| 17 | cnLOH | Recurrent | 2 | 22833442 (2012)[8] | ||
| 17q21.33 and 17qter | Gain | Recurrent | 3 | 24987674 (2014)[2] | ||
| 17q25 | Gain | Recurrent | 2 | 22833442 (2012)[8] | ||
| 18 | 18 | Gain | Recurrent | 2, 3 | 24987674 (2014)[2], 22833442 (2012)[8] | |
| 19 | 19 | Gain | Recurrent | 2 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 19p/ 19p13 | Gain | ICAM4,ICAM4, IBCL2L12, TYK2, IL2, and DNMT1 | Recurrent | 3 | 24987674 (2014)[2], 26912802 (2016)[4], 24757046 (2014)[6] | |
| 19q | Gain | Recurrent | 2 | 24987674 (2014)[2], 25145975 (2015)[3] | ||
| 20 | 20p | Loss | Recurrent | 2 | 24987674 (2014)[2], 22833442 (2012)[8] | |
| 20/20q | Gain | Recurrent | 2 | 24987674 (2014)[2], 22833442 (2012)[8] | ||
| 20/20q | Loss | Recurrent | 3 | 24987674 (2014)[2], 23010713 (2012)[7] | ||
| 21 | 21 | Gain | Recurrent | 1 | 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 22 | 22 | Loss | Recurrent | 2 | 25636340 (2015)[1], 24987674 (2014)[2], 24757046 (2014)[6], 23010713 (2012)[7], 22833442 (2012)[8] | |
| 22q21 | mostly Gain | PRAME | Recurrent, Associated with relapse | 2 | 27811368-(2016)[11] | |
| X | X | Gain/ Loss | Recurrent | 2 | 25145975 (2015)[3], 22833442 (2012)[8] | |
| X | LOH | Recurrent | 2 | 25145975 (2015)[3] | ||
| Xp | Loss | Recurrent | 3 | 24987674 (2014)[2] | ||
| Xp22.33 | Loss | SHOX, CRLF2, IL3RA | Recurrent | 3 | 26912802 (2016)[4] | |
| Xq | Gain (in males) | Poor prognostic marker | 2 | 25636340 (2015)[1], 24987674 (2014)[2] | ||
| Xq | Loss | Recurrent | 3 | 24987674 (2014)[2] | ||
| Xq21.31-q21.32 | Loss | PABPC5, PCDHX | Recurrent | 3 | 26912802 (2016)[4] | |
| Xq27.3-q28 | Gain | AFF2, MTMR1, etc | Recurrent | 3 | 26912802 (2016)[4] | |
| Y | Y | Loss | 2 | 25636340 (2015)[1] | ||
| Genome wide load of CNA > 100Mb | gain/loss | associated with significant change in GEP at relapse | 2 | 27811368-(2016)[11] |
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 B, Hebraud; et al. (2015). "Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience". doi:10.1182/blood-2014-07-587964. PMC 4375107. PMID 25636340.CS1 maint: PMC format (link)
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 2.32 2.33 2.34 2.35 2.36 2.37 2.38 2.39 2.40 2.41 2.42 2.43 2.44 2.45 2.46 2.47 2.48 2.49 2.50 2.51 2.52 2.53 2.54 2.55 J, Smetana; et al. (2014). "Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience". doi:10.1155/2014/209670. PMC 4060785. PMID 24987674.CS1 maint: PMC format (link)
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 M, Kim; et al. (2015). "Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma". PMID 25145975.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 E, Kjeldsen (2016). "Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling". PMID 26912802.
- ↑ 5.0 5.1 5.2 N, Bolli; et al. (2014). "Heterogeneity of genomic evolution and mutational profiles in multiple myeloma". doi:10.1038/ncomms3997. PMC 3905727. PMID 24429703.CS1 maint: PMC format (link)
- ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 6.13 6.14 6.15 6.16 6.17 6.18 6.19 6.20 6.21 6.22 6.23 6.24 6.25 6.26 6.27 6.28 6.29 T, Boneva; et al. (2014). "Can genome array screening replace FISH as a front-line test in multiple myeloma?". PMID 24757046.
- ↑ 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 7.13 7.14 7.15 7.16 7.17 7.18 7.19 7.20 7.21 7.22 Bk, Zehentner; et al. (2012). "Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations". PMID 23010713.
- ↑ 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 8.10 8.11 8.12 8.13 8.14 8.15 8.16 8.17 8.18 8.19 8.20 8.21 8.22 8.23 8.24 8.25 8.26 8.27 8.28 8.29 8.30 M, Stevens-Kroef; et al. (2012). "High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma". PMID 22833442.
- ↑ 9.0 9.1 9.2 9.3 9.4 9.5 N, Bolli; et al. (2016). "A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma". doi:10.1038/bcj.2016.72. PMC 5056967. PMID 27588520.CS1 maint: PMC format (link)
- ↑ K, Rack; et al. (2016). "Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases". PMID 26338801.
- ↑ 11.0 11.1 11.2 11.3 P, Krzeminski; et al. (2016). "Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse". doi:10.18632/oncotarget.13025. PMC 5348347. PMID 27811368.CS1 maint: PMC format (link)
- ↑ H, Chang; et al. (2006). "Analysis of PTEN deletions and mutations in multiple myeloma". PMID 16112193.
- ↑ Jb, Egan; et al. (2012). "Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides". doi:10.1182/blood-2012-01-405977. PMC 3412329. PMID 22529291.CS1 maint: PMC format (link)